Differential protein expression in the hippocampi of resilient individuals identified by digital spatial profiling
Acta Neuropathologica Communications volume 10, Article number: 23 (2022)
Clinical symptoms correlate with underlying neurodegenerative changes in the vast majority of people. However, an intriguing group of individuals demonstrate neuropathologic changes consistent with Alzheimer disease (AD) yet remain cognitively normal (termed “resilient”). Previous studies have reported less overall neuronal loss, less gliosis, and fewer comorbidities in these individuals. Herein, NanoString GeoMx™ Digital Spatial Profiler (DSP) technology was utilized to investigate protein expression differences comparing individuals with dementia and AD neuropathologic change to resilient individuals. DSP allows for spatial analysis of protein expression in multiple regions of interest (ROIs) on formalin-fixed paraffin-embedded sections. ROIs in this analysis were hippocampal neurofibrillary tangle (NFT)-bearing neurons, non-NFT-bearing neurons, and their immediate neuronal microenvironments. Analyses of 86 proteins associated with CNS cell-typing or known neurodegenerative changes in 168 ROIs from 14 individuals identified 11 proteins displaying differential expression in NFT-bearing neurons of the resilient when compared to the demented (including APP, IDH1, CD68, GFAP, SYP and Histone H3). In addition, IDH1, CD68, and SYP were differentially expressed in the environment of NFT-bearing neurons when comparing resilient to demented. IDH1 (which is upregulated under energetic and oxidative stress) and PINK1 (which is upregulated in response to mitochondrial dysfunction and oxidative stress) both displayed lower expression in the environment of NFT-bearing neurons in the resilient. Therefore, the resilient display less evidence of energetic and oxidative stress. Synaptophysin (SYP) was increased in the resilient, which likely indicates better maintenance of synapses and synaptic connections. Furthermore, neurofilament light chain (NEFL) and ubiquitin c-terminal hydrolase (Park5) were higher in the resilient in the environment of NFTs. These differences all suggest healthier intact axons, dendrites and synapses in the resilient. In conclusion, resilient individuals display protein expression patterns suggestive of an environment containing less energetic and oxidative stress, which in turn results in maintenance of neurons and their synaptic connections.
Alzheimer disease neuropathologic change (ADNC) levels of intermediate and high are considered to be sufficient to explain cognitive impairment by current consensus criteria . However, it has been reported that up to 70% of cognitively normal (CN) individuals have some degree of AD pathology at death and about 30% of these CN individuals meet the criteria for intermediate or high ADNC [1, 7, 8, 23, 58]. These CN individuals with intermediate to high ADNC are often described as “cognitively resilient.” Investigations into the unique characteristics of these resilient people have ranged from studies of their clinical and lifestyle differences [1, 10, 21, 42], neuropathologic differences [26, 43, 50], genetic differences [15, 47], brain imaging and metabolic signatures [2, 41, 51], as well as their distinct synaptic characteristics and cytokine profiles [6, 44, 63]. Findings from these studies have revealed higher education levels in the resilient, more engagement in physical and social/mental activities [1, 10, 42], fewer neuropathologic comorbidities [1, 26, 43, 50], single nucleotide polymorphisms (SNPs) related to immune response, as well as vascular, metabolic and mental health being associated with resilience against amyloidosis [15, 47], imaging and metabolic signatures suggesting better maintenance of structure (cortical thickness) and function (FDG-PET) despite AD pathologic change, especially in the anterior cingulate and temporal pole [2, 41, 51], and synapses with fewer tau and Aβ-oligomers in the post-synaptic densities and less ApoE in the pre-synaptic synaptosomes in the resilient [44, 54, 63].
In the neurodegenerative field, one of the only studies published to date which utilized NanoString GeoMx™ DSP, analyzed differential protein expression in and around plaques in cases with AD pathology compared to AD cases with TREM2 variations, using amyloid plaques and their immediate microenvironments as ROIs . They found differences in the AD and TREM2 cases which included increased p-tau in the microenvironment of the plaques of the TREM2 variant carriers, as well as increased NMDAR1 and S100B in the center of the plaques. Given that NFT burden correlates more closely with cognitive status , we used a similar approach, but focused on neurons with and without NFTs.
Herein, we utilized the GeoMx DSP technology to compare NFT-bearing neurons to non-NFT-bearing neurons (as well as their immediate neuronal microenvironments) in cases with AD pathology. Furthermore, we compare NFT-bearing neurons in resilient individuals (non-demented with AD pathology) to NFT-bearing neurons in individuals with dementia and AD pathology, and their immediate neuronal microenvironments, as well as the non-NFT-bearing neurons in these same subgroups.
Materials and methods
We obtained posterior hippocampal sections at the level of the lateral geniculate nucleus (LGN) from 14 patients with histopathologic findings of Alzheimer disease (Table 1). These included 6 demented and 8 resilient, defined using the standard Mini-Mental State Examination (MMSE) and provided cognitive status from The Mitchell Center for Neurodegenerative Diseases at University of Texas Medical Branch and Department of Pathology at Oregon Health and Science University using standard protocols. For our purposes, “demented” was defined as MMSE < 19, and “resilience” was defined as MMSE ≥ 19 with Braak neurofibrillary tangle stage ≥ IV, and age ≥ 87-years-old.
NanoString GeoMx™ DSP
Formalin-fixed paraffin-embedded (FFPE) hippocampal sections were deparaffinized and incubated with a cocktail containing 86 antibodies (Additional file 1), each of which are conjugated to unique UV-photocleavable oligonucleotide tags. Specific fluorescently-labeled antibodies were used as the morphology markers to select regions of interest (ROIs), according to the manufacturer’s instructions using a kit and protocols developed specifically for DSP protein assays (https://www.nanostring.com/products/geomx-digital-spatial-profiler/geomx-protein-assays/). In this study, NFTs, β-amyloid plaques, and microglia were selected as the morphology markers and identified visually by fluorescently-labeled antibodies against AT8 (phospho-tau—Ser202,Thr205) (ThermoFisher Scientific, MN1020, conjugated with AF594 using Alexa Fluor 594 antibody Labeling Kit from Thermo A20185—green), β-amyloid (MOAB-2) (Alexa Fluor 532—aqua) (Novus Biologicals NBP2-1307AF532) and IBA-1 (20A12.1) (Alexa Fluor 647—red) (Millipore Sigma MABN92-AF647). Nuclei were identified by staining with Syto13 (ThermoFisher Scientific), a nucleic acid-binding blue fluorescent dye. In each case, four neurofibrillary tangles in the CA1 subregion of the hippocampus and two non-tangle-bearing (normal) neurons were selected as ROIs for high-resolution multiplex profiling, as well as their respective surrounding microenvironments comprising a total of 12 ROIs per slide. A 10-μm in diameter circle was selected as the center ROI surrounding each neuron, and a 50-μm in diameter concentric circle around the center ROI was selected for the immediate neuronal microenvironment, excluding the central 10-μm region. Overall, we compared 24 demented NFTs to 32 resilient NFTs in one analysis, and 56 NFTs to 28 normal neurons in another analysis, as well as their immediate microenvironments. Examples of our ROIs are demonstrated in Fig. 1. We avoided neurons and NFTs near Aβ plaques. All ROIs were analyzed using an early version of NanoString’s GeoMx™ Digital Spatial Profiler system (NanoString Technologies, Seattle, WA, USA), as described previously . Briefly, in this process, the selected ROIs were illuminated individually via UV light on the GeoMx™ DSP, photocleaving the oligonucleotides from the antibodies bound in the ROIs. The oligonucleotides were collected on a 96-well microwell plate. Individual microwells contain the collected photocleaved oligonucleotides from each spatially resolved ROI. These oligonucleotides were then hybridized to four-color, six-spot optical barcodes and analyzed on the nCounter® platform, resulting in distinct spatially mapped counts that correspond to the amount of each antibody that was present in each ROI. Digital counts were first normalized with internal controls (GAPDH, Histone H3, and S6) for system variation, although these have been shown to have altered expression in neurofibrillary tangles in Alzheimer disease [25, 27], therefore, samples were normalized to spiked-in External RNA Controls Consortium (ERCC) RNA control counts .
DSP analysis and statistics
The raw data included expression levels of 86 proteins and 3 IgG controls in 12 ROIs from each of the 14 cases. Raw data was normalized to ERCC RNA control counts. Data included 6 demented and 8 non-demented (resilient) cases. The mean and median of age were 84 and 87 years old, respectively, with a standard deviation of 11 years. In order to identify the differentially expressed proteins in each comparison, we used the limma package (Version 3.48.1)  and custom R (Version 4.1.0) scripts . The linear regression model was adjusted for sex, age and age squared. The correlation between technical replicates was estimated using duplicateCorrelation  function and then added to the linear model. The p-values were adjusted for multiple analyses using Benjamini–Hochberg with a false discovery rate (FDR) of 0.01. The heatmaps were generated using ComplexHeatmap (Version 2.8.0) .
NFT-bearing neurons vs non-NFT-bearing neurons
Our first analysis of the DSP data compared NFT-bearing neurons (n = 56) to non-NFT-bearing neurons (n = 28) in the CA1 subregion of the hippocampus, using all cases (demented and resilient). Out of the 86 proteins analyzed, 16 were differentially expressed between the neuron groups (i.e., with NFTs versus without NFTs) (Fig. 2, Additional file 2). As expected, levels of total and phosphorylated-tau were increased in the NFT-bearing neurons (i.e., Ser404, Ser214, Ser296, Ser199a and Thr231). Other proteins upregulated in NFT-bearing neurons included those known to be involved in β-amyloid processing including PSEN1 (Presenilin 1, a subunit of the γ-secretase complex that cleaves APP); BACE1 (β-secretase 1, a β-secretase responsible for the first step in the proteolytic cleavage of APP); ADAM10 (A Disintegrin and Metalloproteinase, an α-secretase in neurons responsible for cleaving APP into a neuroprotective fragment that is not capable of plaque formation); neprilysin (CD10, a protease that inactivates several peptide hormones and is involved in the rate limiting step of β-amyloid degradation) and IDE (insulin degrading enzyme, a protease capable of degrading monomeric Aβ). Upregulation of PSEN1 and BACE1 may increase APP processing and downstream Aβ production and deposition, whereas upregulation of ADAM10, neprilysin, and IDE may be protective as they would help degrade the Aβ. We note that the elevated expression of APP and its processing machinery resulted in a modest, non-significant, increase in Aβ42 in NFT-bearing neurons (Additional file 2) suggesting a near balance was met by upregulating both Aβ producing (i.e., APP, PSEN1, BACE1) and degrading proteins (i.e., ADAM10, neprilysin and IDE).
Other notable differentially expressed proteins included Histone H3 and Ki-67. Their expression patterns in NFT-bearing neurons (lower and higher, respectively) is consistent with chromatin remodeling and potential exit from quiescence  which have been linked to pathogenic tau accumulation  and senescence [13, 37]. We also found elevated TDP-43 and ubiquitin in NFT-bearing neurons. These findings may signify a dysfunctional ubiquitin proteasome system, which has been mechanistically linked to tauopathy  resulting in the accumulation of multiple proteins (i.e., tau, TDP-43 and UBB) in NFT-bearing neurons.
This same analysis was performed separately within each subgroup (demented and resilient) as well. The two subgroups have many overlapping differentially expressed proteins when comparing their NFT-bearing neurons to non-NFT-bearing neurons (Fig. 3a., Additional file 3a. and Fig. 3b., Additional file 4b.). However, the resilient do not have APP, BACE1 or Ki-67 upregulated in their NFT-bearing neurons as the demented do, yet they do have ADAM10 upregulated, whereas the demented do not have ADAM10 upregulated. This suggests that the resilient may develop tangles without subsequent changes in several deleterious proteins related to β-amyloid processing, but may have more of the protective proteins. In addition, Ki-67 is not increased in the resilient, which could suggest less entry into a senescence phenotype in the resilient.
We also compared the immediate neuronal microenvironments of the NFT-bearing neurons and the non-NFT-bearing neurons, regardless of cognitive status. In this analysis we found that only levels of phosphorylated-tau differed (Fig. 4, Additional file 5); specifically, p-tau Thr231, Ser199, Ser396, and Ser214 were upregulated in the microenvironments of the NFTs. Of note, neither total tau nor Ser404 expression differed between the microenvironments indicating distinct spatial distributions among the elevated tau species.
Resilient vs demented
Our next set of analyses were designed to compare the resilient (AD pathology without dementia) to the demented (AD pathology with dementia). Comparing NFT-bearing neurons between resilient and demented, we identified 11 proteins with significantly different expression (Fig. 5, Additional file 6). Most of these displayed lower expression in the resilient individuals, and included proteins involved in β-amyloid processing such as APP, neprilysin, and IDE; proteins associated with proteostasis such as ubiquitin and p-tau; and proteins involved in neuroinflammation such as GFAP and CD68. Histone H3 expression was also found to be expressed at significantly lower levels in the resilient NFT-bearing neurons than NFT-bearing neurons from demented. In addition, tau phosphorylated at Serine 396 and 404 were lower in the tangles of the resilient. Interestingly, these two site-specific post-translational modifications of tau are thought to be more abundant in later stages of AD . Furthermore, it has been reported that phosphorylation of tau at these 2 sites (S396 and S404) leads to inhibition of its normal function . This raises the possibility that in avoiding phosphorylation at these sites, neurons in resilient individuals are able to maintain normal tau function and neuronal stability, despite the presence of tangles. Additional evidence supporting that NFT-bearing neurons from resilient cases may be better maintained was the observed increased expression of synaptophysin (SYP) in NFT-bearing neurons of the resilient individuals.
We next identified proteins that displayed significantly different expression in the environment of the tangle-bearing neurons in the demented individuals as compared to the resilient (Fig. 6, Additional file 7). In this scenario, CD68, CD39 and GFAP were lower in the resilient (indicative of less inflammation). Other proteins with lower expression levels in the environment of NFT-bearing neurons of the resilient as compared to cases with dementia included PTEN induced kinase 1 (PINK1), a mitochondrial protein that is upregulated during cellular stress and unusually high energy demands , and NADP + -dependent isocitrate dehydrogenase 1 (IDH1), an enzyme critical to glucose metabolism and the primary producer of brain NADPH . These proteins are generally upregulated in response to energetic or oxidative stress. Therefore, the resilient individuals likely maintain a lower burden of oxidative stress. The proteins with higher expression in the environment of the tangles in the resilient individuals as compared to the demented were proteins indicative of healthy neuronal structure and function (i.e., synaptophysin, neurofilament light chain, and post-synaptic density protein 95 (PSD-95)). Park5, a ubiquitin c-terminal hydrolase important for stabilizing monomeric ubiquitin that has been reported to be decreased in AD brains , and ribosomal protein S6 were also higher in resilient cases compared to those with dementia. The increased abundance of these proteins suggests healthier intact axons, dendrites and synapses in the resilient.
When comparing the inner circle ROIs around non-tangle-bearing neurons of the demented and resilient (i.e., the cell bodies of neurons without AT8-positive tau across cases), there were no significant differences in protein expression (Additional file 8a.). However, when comparing their immediate microenvironments, we observed significant differences whereby resilient cases displayed higher levels of synaptophysin, and lower levels of PINK1, IDH1, CD68, and p-tau S396 than demented cases (Fig. 7, Additional file 9b.). These data suggest that microenvironment differences may be impacting cognitive resilience, even in neurons without tau pathology.
Upon review of the hippocampal sections stained with the morphology markers, we observed that the resilient harbored less neurofibrillary degeneration and plaque deposition overall in the hippocampal CA subregions as compared to the demented. In addition, we observed abundant quiescent (resting) microglia in the resilient hippocampi (Fig. 8), although there were frequent activated microglia attacking neuritic plaques in the fusiform cortex (Fig. 9).
Understanding that the average Braak stage is lower in the resilient subgroup (median Braak stage IV–V in the resilient vs. VI in the demented), we also analyzed protein expression differences in the NFTs of the all of the Braak stage IV cases vs. all of the Braak stage VI cases, regardless of cognitive status. The only significant differences in protein expression in the hippocampal NFTs of these 2 subgroups are p-tau S396 and S404 displaying higher expression in the Braak stage VI cases (two epitopes of p-tau that are observed in later stages of AD) [39, 48], which suggests that the protein differences associated with neuroinflammation and increased oxidative stress observed in the demented are not associated with the higher Braak stage in this instance, but more with cognitive status (Additional file 10).
Utilizing digital spatial profiling, we have demonstrated that neurofibrillary tangles not only express high levels of phosphorylated-tau as expected, but they also upregulate proteins related to β-amyloid processing. This raises the age-old “chicken or the egg” question of which comes first, the p-tau or the β-amyloid; our data suggest that it may be the NFT-bearing neurons that contribute more to Aβ production than neurons without phosphorylated-tau (i.e., Fig. 2). NFT formation begins in the locus coeruleus in people in their teens to 20s (and all adults examined develop some degree of neurofibrillary degeneration in their lifetime) . Whereas β-amyloid diffuse plaques begin in the neocortex in some people in their 40s-50s (but not all people develop plaques in their lifetime) . The hippocampus is a nexus for the progression of both plaques and tangles. At Thal phase 2, plaques reach the entorhinal cortex and CA1 subregion of the hippocampus, then the molecular layer of the dentate gyrus at Thal phase 3, and the CA4 subregion at Thal phase 4. At Braak stage III, the CA1 subregion of the hippocampus harbors a substantial amount of neurofibrillary degeneration. Thus, the entorhinal cortex and hippocampus are where plaques and tangles initially “encounter” each other. It is difficult to say which comes first, however, our data may suggest that the NFTs in the demented are involved in instigating and/or regulating β-amyloid plaque deposition. Since it is known that plaques exist in the neocortex without tangles, this cannot be the case everywhere. Neuritic plaques, however, do appear only after neurofibrillary degeneration and plaque formation have coincided (first in the entorhinal cortex and hippocampus). Perhaps then, the demented have upregulated proteins within the NFTs that instigate the formation of neuritic plaques, rather than just diffuse plaques. Thal phase (stage of diffuse plaque deposition) does not correlate well with cognition, but CERAD neuritic plaque score does generally correlate well with cognition . This raises the possibility that the demented are more inclined to form deleterious neuritic plaques, or vice versa.
It is true that only APP, neprilysin, and IDE display increased expression in the tangles of the demented when compared to the resilient, and neprilysin and IDE would both be protective. However, it is likely that the resilient do not need to upregulate neprilysin and IDE as much because they do not have APP upregulated in parallel. Also, when comparing the subgroups separately, the NFTs of the resilient did not upregulate BACE1 or APP. While these proteins are infamously known for their role in Aβ production and degradation; importantly, they also regulate other diverse cellular functions. One shared pathway among many of them is neuronal insulin sensitivity. Specifically, BACE1 expression levels inversely correlate with body weight, lipid and glucose homeostasis ; PSEN1 directly downregulates the expression of insulin receptor ; neprilysin upregulation is correlated with insulin resistance  while its decrease is associated with enhanced insulin sensitivity [61, 64]; IDE directly degrades insulin [34, 35] and is upregulated in brain cells with aberrant cell cycle activity . These data build on prior reports showing aberrant insulin signaling in NFT-bearing neurons including phosphorylated insulin receptor substrate 1 (IRS1) at serine residues linked to insulin resistance . Additionally, our data revealed a significant difference in synaptic proteins between neurons with or without NFT, which is a key feature of insulin resistant senescent neurons . The activation of the cellular senescence stress response in NFT-bearing neurons was further supported in our dataset by aberrant Histone H3 and Ki-67 expression (Fig. 2).
In addition, we demonstrate that the areas of neurofibrillary degeneration in the resilient express lower levels of GFAP and CD68, indicative of less inflammation. These data suggest that lower levels of inflammation, despite neuropathology, may be contributing to cognitive resilience in the cases analyzed here. An increase in GFAP (or gliosis) generally occurs after neuronal loss. This aligns with observations of more neuronal loss in demented individuals, and suggests neuronal maintenance may be better achieved in the absence of GFAP and CD68 upregulation. Of note, we did not observe significant differences in microglia markers Iba1, P2ry12, TREM119, CD11b, CD163, CD40 and CD45, though we did observe lower CD68, commonly considered a marker of activated microglia, in the resilient. Together, these data suggest that total microglia may be comparable between resilient and demented, whereas activated microglia are more closely associated with dementia.
Furthermore, analyses revealed lower levels of proteins which respond to cellular stress or unusually high energy demands such as PINK1 and IDH1, in the resilient. PINK1 (PTEN-induced kinase) is a serine/threonine protein kinase that is upregulated in the mitochondria in times of cellular stress. IDH1 (isocitrate dehydrogenase) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate to alpha-ketoglutarate, resulting in the production of NADPH from NADP + . IDH1 is upregulated under oxidative stress in order to limit oxidative damage . This suggests there is a lower abundance of oxidative stress in the resilient. The resilient also displayed higher levels of synaptophysin, neurofilament light chain (NFL) and Park5. NFL has been reported to be increased in the CSF of AD patients, indicating degradation of neurons and their axons. However, if one has more NFL in the parenchyma, as the resilient do, it is indicative of healthier and intact axons. Park5 expression is lower in AD brains and an increased level of Park5 is thought to be protective for synaptic and cognitive function. Overall, there is less evidence of energetic and oxidative stress, lower neuroinflammation, and more evidence for healthy, intact axons and synapses in the resilient.
Although all but one of the resilient cases have sufficient pathology to qualify for a diagnosis of intermediate or high ADNC, they do display a lower abundance of neurofibrillary tangles and plaques in the hippocampus (by observation), and therefore harbor a lower total burden of AD pathology in the hippocampus. This could be significantly contributing to their superior cognition and cannot be overlooked. However, the differences we found in protein expression within the tangles (most notably molecular machinery critical to Aβ generation, insulin signaling, protein accumulation and cellular senescence) and their microenvironments demonstrate that there are multiple factors contributing to the ability of the resilient to protect themselves in the face of the neurofibrillary degeneration. These factors may also play a role in reducing the development of more widespread abundant AD pathology as would occur through increased Aβ production and cellular senescence-associated inflammation. It is also important to note that these cases do not have significant comorbid pathologies, as multiple studies have demonstrated that the presence of concomitant pathologies is common in AD, and these can significantly affect cognition [4, 24, 30].
Previous studies have examined transcriptomic gene expression changes within neurofibrillary tangles [13, 16, 29] and in AD brains , however many of the genes that are upregulated do not correlate well with protein expression changes. In the prefrontal cortex, GFAP gene expression was found to be upregulated in AD brains , and in CA1 pyramidal neurons gene expression of synaptophysin and PSD-95 were downregulated in individuals with MCI and AD , corroborating our findings of preservation of synaptophysin and PSD-95 protein expression in the resilient hippocampi. There have not been many published -omic studies investigating resilience. One genome-wide association study (GWAS) examined SNPs associated with resilience against amyloidosis and found differences in genetic drivers of bile acid homeostasis, vascular and metabolic risk factors, and neuropsychiatric conditions between resilient and demented individuals .
In addition, studies have used affinity purification mass-spectrometry (AP-MS) to investigate protein interactions with phosphorylated-tau [5, 14, 22, 32], identifying several proteins that overlap with our findings including TDP-43, MAP2, GFAP, UBB, and IDH. We found that UBB, GFAP, and IDH were lower in the NFTs of the resilient as compared to the demented, as were p-tau S396 and S404. Interestingly, Drummond et al. identified p-tau using PHF-1 which recognizes tau phosphorylated at S396 and S404 , and so their study may have preferentially found proteins that are upregulated at later stages of AD and primarily in the demented.
In light of the significant findings of this study, there are several limitations that should be noted. Firstly, we were limited in the number of cases (8) with sufficient clinical and pathologic data to be classified as “resilient” as truly resilient cases are quite rare in neurodegenerative and community-based brain banks and many post-mortem studies of dementia and resilience have fewer than 10 resilient cases [26, 43]. Additionally, more detailed correlations between MMSE scores and other factors were not possible to make with the present data, as a number of the “demented” cases did not have definitive MMSE values, only that they were < 19 to qualify as “demented” (Table 1). In addition, the number of regions of interest per slide was limited to 12. However, the DSP technology has a number of benefits over more traditional means. This methodology combines both spatial and quantitative capabilities, and as such can perform very granular quantification of proteins in well-defined, restricted areas, in an unbiased manner unlike traditional immunohistochemical staining, which can identify specific proteins, but does not add much quantitative value, and western blotting or proteomics mass spectrometry, which can provide accurate quantification but does not have the spatial localization ability of DSP.
This spatial proteomic study of resilience in the face of AD neuropathologic change is a unique investigation providing novel findings that advance our understanding of the mechanisms by which some individuals are able to evade cognitive decline despite the presence of Alzheimer disease pathologic changes. By utilizing NanoString GeoMx™ DSP, we found that NFT-bearing neurons display increased expression of several proteins involved in β-amyloid processing, which reinforces the assumption that tangle and plaque pathology may develop synergistically in AD. However, there was significantly lower expression of β-amyloid processing proteins in the tangles of resilient individuals. In addition, the resilient individuals displayed lower expression of proteins involved in neuroinflammation, and a protein signature suggestive of an environment containing less energetic and oxidative stress, and more amenable to the maintenance of neuronal integrity and synaptic connections.
A disintegrin and metalloproteinase domain-containing protein 10
Alzheimer disease neuropathologic change
Amyloid precursor protein
Consortium to Establish a Registry for Alzheimer Disease
Cluster of differentiation 68
Digital spatial profiler
External RNA Controls Consortium
Glial fibrillary acidic protein
Ionized calcium binding adaptor molecule 1
Insulin degrading enzyme
- NEFL (NFL):
Neurofilament light chain
Mini-metal state examination
- Park5 (UCH-L1):
Ubiquitin c-terminal hydrolase
PTEN induced kinase
Region of interest
Single nucleotide polymorphism
TAR DNA-binding protein
Aiello Bowles EJ, Crane PK, Walker RL, Chubak J, LaCroix AZ, Anderson ML, Rosenberg D, Keene CD, Larson EB (2019) Cognitive resilience to Alzheimer’s disease pathology in the human brain. J Alzheimers Dis 68:1071–1083. https://doi.org/10.3233/JAD-180942
Arenaza-Urquijo EM, Przybelski SA, Lesnick TL, Graff-Radford J, Machulda MM, Knopman DS, Schwarz CG, Lowe VJ, Mielke MM, Petersen RC et al (2019) The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. Brain 142:1134–1147. https://doi.org/10.1093/brain/awz037
Atai NA, Renkema-Mills NA, Bosman J, Schmidt N, Rijkeboer D, Tigchelaar W, Bosch KS, Troost D, Jonker A, Bleeker FE et al (2011) Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma. J Histochem Cytochem 59:489–503. https://doi.org/10.1369/0022155411400606
Attems J, Jellinger K (2013) Neuropathological correlates of cerebral multimorbidity. Curr Alzheimer Res 10:569–577. https://doi.org/10.2174/15672050113109990002
Ayyadevara S, Balasubramaniam M, Parcon PA, Barger SW, Griffin WST, Alla R, Tackett AJ, Mackintosh SG, Petricoin E, Zhou W et al (2016) Proteins that mediate protein aggregation and cytotoxicity distinguish Alzheimer’s hippocampus from normal controls. Aging Cell 15:924–939. https://doi.org/10.1111/acel.12501
Barroeta-Espar I, Weinstock LD, Perez-Nievas BG, Meltzer AC, Siao Tick Chong M, Amaral AC, Murray ME, Moulder KL, Morris JC, Cairns NJ et al (2019) Distinct cytokine profiles in human brains resilient to Alzheimer’s pathology. Neurobiol Dis 121:327–337. https://doi.org/10.1016/j.nbd.2018.10.009
Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS (2006) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66:1837–1844. https://doi.org/10.1212/01.wnl.0000219668.47116.e6
Boyle PA, Yu L, Wilson RS, Schneider JA, Bennett DA (2013) Relation of neuropathology with cognitive decline among older persons without dementia. Front Aging Neurosci 5:50. https://doi.org/10.3389/fnagi.2013.00050
Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70:960–969. https://doi.org/10.1097/NEN.0b013e318232a379
Casaletto KB, Renteria MA, Pa J, Tom SE, Harrati A, Armstrong NM, Rajan KB, Mungas D, Walters S, Kramer J et al (2020) Late-life physical and cognitive activities independently contribute to brain and cognitive resilience. J Alzheimers Dis 74:363–376. https://doi.org/10.3233/JAD-191114
Chow HM, Shi M, Cheng A, Gao Y, Chen G, Song X, So RWL, Zhang J, Herrup K (2019) Age-related hyperinsulinemia leads to insulin resistance in neurons and cell-cycle-induced senescence. Nat Neurosci 22:1806–1819. https://doi.org/10.1038/s41593-019-0505-1
Counts SE, Alldred MJ, Che S, Ginsberg SD, Mufson EJ (2014) Synaptic gene dysregulation within hippocampal CA1 pyramidal neurons in mild cognitive impairment. Neuropharmacology 79:172–179. https://doi.org/10.1016/j.neuropharm.2013.10.018
Dehkordi SK, Walker J, Sah E, Bennett E, Atrian F, Frost B, Woost B, Bennett RE, Orr TC, Zhou Y et al (2021) Profiling senescent cells in human brains reveals neurons with CDKN2D/p19 and tau neuropathology. Nat Aging. https://doi.org/10.1038/s43587-021-00142-3
Drummond E, Pires G, MacMurray C, Askenazi M, Nayak S, Bourdon M, Safar J, Ueberheide B, Wisniewski T (2020) Phosphorylated tau interactome in the human Alzheimer’s disease brain. Brain 143:2803–2817. https://doi.org/10.1093/brain/awaa223
Dumitrescu L, Mahoney ER, Mukherjee S, Lee ML, Bush WS, Engelman CD, Lu Q, Fardo DW, Trittschuh EH, Mez J et al (2020) Genetic variants and functional pathways associated with resilience to Alzheimer’s disease. Brain 143:2561–2575. https://doi.org/10.1093/brain/awaa209
Dunckley T, Beach TG, Ramsey KE, Grover A, Mastroeni D, Walker DG, LaFleur BJ, Coon KD, Brown KM, Caselli R et al (2006) Gene expression correlates of neurofibrillary tangles in Alzheimer’s disease. Neurobiol Aging 27:1359–1371. https://doi.org/10.1016/j.neurobiolaging.2005.08.013
Evans DB, Rank KB, Bhattacharya K, Thomsen DR, Gurney ME, Sharma SK (2000) Tau phosphorylation at serine 396 and serine 404 by human recombinant tau protein kinase II inhibits tau’s ability to promote microtubule assembly. J Biol Chem 275:24977–24983. https://doi.org/10.1074/jbc.M000808200
Frost B, Hemberg M, Lewis J, Feany MB (2014) Tau promotes neurodegeneration through global chromatin relaxation. Nat Neurosci 17:357–366. https://doi.org/10.1038/nn.3639
Gong B, Cao Z, Zheng P, Vitolo OV, Liu S, Staniszewski A, Moolman D, Zhang H, Shelanski M, Arancio O (2006) Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 126:775–788. https://doi.org/10.1016/j.cell.2006.06.046
Gu Z, Eils R, Schlesner M (2016) Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32:2847–2849. https://doi.org/10.1093/bioinformatics/btw313
Hayden KM, Gaussoin SA, Hunter JC, Manson JE, Sachs BC, Shadyab AH, Tindle HA, Mossavar-Rahmani Y, Mozhui K, Snively BM et al (2019) Cognitive resilience among APOE epsilon4 carriers in the oldest old. Int J Geriatr Psychiatry 34:1833–1844. https://doi.org/10.1002/gps.5199
Hsieh Y, Guo C, Yalamanchili HK, Abreha M, Al-Ouran R, Li Y, Dammer EB, Lah JJ, Levey AI, Bennett DA et al (2019) Tau-mediated disruption of the spliceosome triggers cryptic RNA splicing and neurodegeneration in Alzheimer’s disease. Cell Rep 29:301-316.e310. https://doi.org/10.1016/j.celrep.2019.08.104
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14:535–562. https://doi.org/10.1016/j.jalz.2018.02.018
Jellinger KA, Attems J (2015) Challenges of multimorbidity of the aging brain: a critical update. J Neural Transm (Vienna) 122:505–521. https://doi.org/10.1007/s00702-014-1288-x
Koren SA, Hamm MJ, Meier SE, Weiss BE, Nation GK, Chishti EA, Arango JP, Chen J, Zhu H, Blalock EM et al (2019) Tau drives translational selectivity by interacting with ribosomal proteins. Acta Neuropathol 137:571–583. https://doi.org/10.1007/s00401-019-01970-9
Latimer CS, Burke BT, Liachko NF, Currey HN, Kilgore MD, Gibbons LE, Henriksen J, Darvas M, Domoto-Reilly K, Jayadev S et al (2019) Resistance and resilience to Alzheimer’s disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort. Acta Neuropathol Commun 7:91. https://doi.org/10.1186/s40478-019-0743-1
Li R, Shen Y (2013) An old method facing a new challenge: re-visiting housekeeping proteins as internal reference control for neuroscience research. Life Sci 92:747–751. https://doi.org/10.1016/j.lfs.2013.02.014
Maesako M, Uemura K, Kuzuya A, Sasaki K, Asada M, Watanabe K, Ando K, Kubota M, Akiyama H, Takahashi R et al (2012) Gain of function by phosphorylation in Presenilin 1-mediated regulation of insulin signaling. J Neurochem 121:964–973. https://doi.org/10.1111/j.1471-4159.2012.07741.x
Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, Menon M, He L, Abdurrob F, Jiang X et al (2019) Single-cell transcriptomic analysis of Alzheimer’s disease. Nature 570:332–337. https://doi.org/10.1038/s41586-019-1195-2
McAleese KE, Colloby SJ, Thomas AJ, Al-Sarraj S, Ansorge O, Neal J, Roncaroli F, Love S, Francis PT, Attems J (2021) Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia. Alzheimers Dement 17:1121–1133. https://doi.org/10.1002/alz.12291
Meakin PJ, Harper AJ, Hamilton DL, Gallagher J, McNeilly AD, Burgess LA, Vaanholt LM, Bannon KA, Latcham J, Hussain I et al (2012) Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice. Biochem J 441:285–296. https://doi.org/10.1042/BJ20110512
Meier SE, Bell M, Lyons DN, Ingram A, Chen J, Gensel JC, Zhu H, Nelson PT, Abisambra JF (2015) Identification of novel Tau interactions with endoplasmic reticulum proteins in Alzheimer’s disease brain. J Alzheimers Dis 48:687–702. https://doi.org/10.3233/JAD-150298
Merritt CR, Ong GT, Church SE, Barker K, Danaher P, Geiss G, Hoang M, Jung J, Liang Y, McKay-Fleisch J et al (2020) Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat Biotechnol 38:586–599. https://doi.org/10.1038/s41587-020-0472-9
Mirsky IA, Broh-Kahn RH (1949) The inactivation of insulin by tissue extracts; the distribution and properties of insulin inactivating extracts. Arch Biochem 20:1–9
Mirsky IA, Simkin B, Broh-Kahn RH (1950) The inactivation of insulin by tissue extracts. VI. The existence, distribution and properties of an insulinase inhibitor. Arch Biochem 28:415–423
Montine TJ, Monsell SE, Beach TG, Bigio EH, Bu Y, Cairns NJ, Frosch M, Henriksen J, Kofler J, Kukull WA et al (2016) Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer’s disease. Alzheimers Dement 12:164–169. https://doi.org/10.1016/j.jalz.2015.07.492
Musi N, Valentine JM, Sickora KR, Baeuerle E, Thompson CS, Shen Q, Orr ME (2018) Tau protein aggregation is associated with cellular senescence in the brain. Aging Cell 17:e12840. https://doi.org/10.1111/acel.12840
Myeku N, Clelland CL, Emrani S, Kukushkin NV, Yu WH, Goldberg AL, Duff KE (2016) Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat Med 22:46–53. https://doi.org/10.1038/nm.4011
Neddens J, Temmel M, Flunkert S, Kerschbaumer B, Hoeller C, Loeffler T, Niederkofler V, Daum G, Attems J, Hutter-Paier B (2018) Phosphorylation of different tau sites during progression of Alzheimer’s disease. Acta Neuropathol Commun 6:52. https://doi.org/10.1186/s40478-018-0557-6
O’Sullivan RJ, Kubicek S, Schreiber SL, Karlseder J (2010) Reduced histone biosynthesis and chromatin changes arising from a damage signal at telomeres. Nat Struct Mol Biol 17:1218–1225. https://doi.org/10.1038/nsmb.1897
Ossenkoppele R, Lyoo CH, Jester-Broms J, Sudre CH, Cho H, Ryu YH, Choi JY, Smith R, Strandberg O, Palmqvist S et al (2020) Assessment of demographic, genetic, and imaging variables associated with brain resilience and cognitive resilience to pathological tau in patients with Alzheimer disease. JAMA Neurol 77:632–642. https://doi.org/10.1001/jamaneurol.2019.5154
Paganini-Hill A, Kawas CH, Corrada MM (2016) Lifestyle factors and dementia in the oldest-old: the 90+ study. Alzheimer Dis Assoc Disord 30:21–26. https://doi.org/10.1097/WAD.0000000000000087
Perez-Nievas BG, Stein TD, Tai HC, Dols-Icardo O, Scotton TC, Barroeta-Espar I, Fernandez-Carballo L, de Munain EL, Perez J, Marquie M et al (2013) Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology. Brain 136:2510–2526. https://doi.org/10.1093/brain/awt171
Phongpreecha T, Gajera CR, Liu CC, Vijayaragavan K, Chang AL, Becker M, Fallahzadeh R, Fernandez R, Postupna N, Sherfield E, et al (2021) Single-synapse analyses of Alzheimer’s disease implicate pathologic tau, DJ1, CD47, and ApoE. bioRxiv. Doi:https://doi.org/10.1101/2021.06.14.448240
Pine PS, Munro SA, Parsons JR, McDaniel J, Lucas AB, Lozach J, Myers TG, Su Q, Jacobs-Helber SM, Salit M (2016) Evaluation of the External RNA Controls Consortium (ERCC) reference material using a modified Latin square design. BMC Biotechnol 16:54. https://doi.org/10.1186/s12896-016-0281-x
Prokop S, Miller KR, Labra SR, Pitkin RM, Hoxha K, Narasimhan S, Changolkar L, Rosenbloom A, Lee VM, Trojanowski JQ (2019) Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimer’s disease patient brain samples. Acta Neuropathol 138:613–630. https://doi.org/10.1007/s00401-019-02048-2
Ramanan VK, Lesnick TG, Przybelski SA, Heckman MG, Knopman DS, Graff-Radford J, Lowe VJ, Machulda MM, Mielke MM, Jack CR, Jr.et al, (2021) Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer’s pathophysiology. Acta Neuropathol Commun 9:48. https://doi.org/10.1186/s40478-021-01154-1
Regalado-Reyes M, Furcila D, Hernandez F, Avila J, DeFelipe J, Leon-Espinosa G (2019) Phospho-tau changes in the human CA1 during Alzheimer’s disease progression. J Alzheimers Dis 69:277–288. https://doi.org/10.3233/JAD-181263
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43:e47. https://doi.org/10.1093/nar/gkv007
Robinson JL, Corrada MM, Kovacs GG, Dominique M, Caswell C, Xie SX, Lee VM, Kawas CH, Trojanowski JQ (2018) Non-Alzheimer’s contributions to dementia and cognitive resilience in The 90+ Study. Acta Neuropathol 136:377–388. https://doi.org/10.1007/s00401-018-1872-5
Rogalski EJ, Gefen T, Shi J, Samimi M, Bigio E, Weintraub S, Geula C, Mesulam MM (2013) Youthful memory capacity in old brains: anatomic and genetic clues from the Northwestern SuperAging Project. J Cogn Neurosci 25:29–36. https://doi.org/10.1162/jocn_a_00300
Sekine S, Youle RJ (2018) PINK1 import regulation; a fine system to convey mitochondrial stress to the cytosol. BMC Biol 16:2. https://doi.org/10.1186/s12915-017-0470-7
Serrano-Pozo A, Qian J, Muzikansky A, Monsell SE, Montine TJ, Frosch MP, Betensky RA, Hyman BT (2016) Thal amyloid stages do not significantly impact the correlation between neuropathological change and cognition in the Alzheimer disease continuum. J Neuropathol Exp Neurol 75:516–526. https://doi.org/10.1093/jnen/nlw026
Singh A, Allen D, Fracassi A, Tumurbaatar B, Natarajan C, Scaduto P, Woltjer R, Kayed R, Limon A, Krishnan B et al (2020) Functional integrity of synapses in the central nervous system of cognitively intact individuals with high Alzheimer’s disease neuropathology is associated with absence of synaptic tau oligomers. J Alzheimers Dis 78:1661–1678. https://doi.org/10.3233/JAD-200716
Smyth GK, Michaud J, Scott HS (2005) Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21:2067–2075. https://doi.org/10.1093/bioinformatics/bti270
Standeven KF, Hess K, Carter AM, Rice GI, Cordell PA, Balmforth AJ, Lu B, Scott DJ, Turner AJ, Hooper NM et al (2011) Neprilysin, obesity and the metabolic syndrome. Int J Obes (Lond) 35:1031–1040. https://doi.org/10.1038/ijo.2010.227
Team RC (2021) R: A language and environment for statistical computing. R Foundation for Statistical Computing. https://www.R-project.org/
Tomlinson BE, Blessed G, Roth M (1968) Observations on the brains of non-demented old people. J Neurol Sci 7:331–356. https://doi.org/10.1016/0022-510x(68)90154-8
Tundo GR, Sbardella D, Ciaccio C, Bianculli A, Orlandi A, Desimio MG, Arcuri G, Coletta M, Marini S (2013) Insulin-degrading enzyme (IDE): a novel heat shock-like protein. J Biol Chem 288:2281–2289. https://doi.org/10.1074/jbc.M112.393108
Wahl DR, Dresser J, Wilder-Romans K, Parsels JD, Zhao SG, Davis M, Zhao L, Kachman M, Wernisch S, Burant CF et al (2017) Glioblastoma therapy can be augmented by targeting IDH1-mediated NADPH biosynthesis. Cancer Res 77:960–970. https://doi.org/10.1158/0008-5472.CAN-16-2008
Willard JR, Barrow BM, Zraika S (2017) Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels. Diabetologia 60:701–708. https://doi.org/10.1007/s00125-016-4172-4
Yarchoan M, Toledo JB, Lee EB, Arvanitakis Z, Kazi H, Han LY, Louneva N, Lee VM, Kim SF, Trojanowski JQ et al (2014) Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer’s disease and tauopathies. Acta Neuropathol 128:679–689. https://doi.org/10.1007/s00401-014-1328-5
Zolochevska O, Bjorklund N, Woltjer R, Wiktorowicz JE, Taglialatela G (2018) Postsynaptic proteome of non-demented individuals with Alzheimer’s disease neuropathology. J Alzheimers Dis 65:659–682. https://doi.org/10.3233/JAD-180179
Zraika S, Koh DS, Barrow BM, Lu B, Kahn SE, Andrikopoulos S (2013) Neprilysin deficiency protects against fat-induced insulin secretory dysfunction by maintaining calcium influx. Diabetes 62:1593–1601. https://doi.org/10.2337/db11-1593
We acknowledge support from the Reed Precision Medicine Initiative, J.M.R. Barker Foundation and the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at the Joe and Teresa Long School of Medicine, University of Texas Health Sciences Center, San Antonio, TX. In addition, the authors would like to thank all of the brain donors for allowing this work to be possible.
This work is supported by NIH/NIA R01AG068293, Cure Alzheimer’s Fund, Veterans Affairs K2BX003804 and a New Vision Research Investigator Award to Dr. Miranda Orr. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. J.M.W. and T.E.R. are supported in part by National Institute on Aging (NIA) P30AG066546 (South Texas Alzheimer’s Disease Research Center). J.M.W. is also supported by the San Antonio Claude D. Pepper Older Americans Independence Center, P30AG044271.
Ethics approval and consent to participate
De-identified postmortem tissue was provided by the Department of Pathology at Oregon Health and Science University in accordance with their Institutional Review Board and is considered exempt from IRB approval.
Consent for publication
Availability of data and material
All data generated or analyzed during this study are included in this published article and its supplementary information files.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
: DSP antibody probes analyzed (86 proteins)
: Differential expression of proteins when comparing neurofibrillary tangle (NFT)-bearing neurons to normal non-NFT-bearing neurons
: Differential expression of proteins when comparing NFT-bearing neurons to non-NFT-bearing neurons in demented only
: NFT-bearing neurons to non-NFT-bearing neurons in resilient only
: Differential expression of proteins when comparing the immediate neuronal microenvironments of NFTs to the microenvironment of normal non-tangle-bearing neurons
: Differential expression of proteins when comparing NFT-bearing neurons of the resilient (non-demented with AD pathology) to NFT-bearing neurons of the demented with AD pathology
: Differential expression of proteins when comparing the immediate neuronal microenvironment of NFT-bearing neurons in the resilient (non-demented with AD pathology) to the immediate neuronal microenvironment of NFT-bearing neurons in the demented with AD pathology
: Differential expression of proteins when comparing normal (non-NFT-bearing neurons) of the resilient to non-NFT-bearing neurons of the demented with no significant differences
: Differential expression of proteins when comparing the immediate neuronal microenvironment of non-NFT-bearing neurons in the resilient to the immediate neuronal microenvironment of non-NFT-bearing neurons in the demented
: Differential expression of proteins when comparing NFT-bearing neurons of all Braak stage IV cases to NFTs of all Braak stage VI cases
About this article
Cite this article
Walker, J.M., Kazempour Dehkordi, S., Fracassi, A. et al. Differential protein expression in the hippocampi of resilient individuals identified by digital spatial profiling. acta neuropathol commun 10, 23 (2022). https://doi.org/10.1186/s40478-022-01324-9
- Alzheimer disease
- Neurofibrillary tangles
- Digital spatial profiling (DSP)